Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy.
Some patients with dilated cardiomyopathy who are inotrope dependent but remain well by undergoing infusions can be managed by ambulatory infusions at home. We report our results in 20 patients awaiting heart transplantation, unable to be weaned from intravenous inotropic therapy on 2 or more occasions, but who were well while receiving inotropes and received home ambulatory infusions. The patients were treated with ACE inhibitors, digoxin, diuretics, vasodilators, close electrolyte management, and low-dose amiodarone for those with more than four-beat ventricular tachycardia. Infusions were delivered by a tunneled subclavian catheter and syringe driver. Thirteen patients received dopamine, four received dobutamine, and three received both. Mean duration of inotropic therapy was 5 months with 70% of the time spent as an outpatient. Eleven patients received transplants, two remain on the waiting list, and seven died after being removed from the list because of general deterioration or renal dysfunction. There were no sudden deaths. Actuarial survival was 71% at 3 months, which is not less than that expected for an inotrope-dependent population. All patients with idiopathic dilated cardiomyopathy survived to transplantation. In contrast, all three with right heart failure caused by pulmonary vascular disease and four of seven with ischemic cardiomyopathy died. Inpatient days were reduced by 70%, leading to considerable cost savings. Home ambulatory inotropic therapy is safe, cost-effective, best suited to those with idiopathic dilated cardiomyopathy, and dramatically reduces inpatient hospital duration.
Sindone
A P
AP
Heart and Lung Transplant Unit, St. Vincent's Hospital, NSW, Sydney, Australia.
Keogh
A M
AM
Macdonald
P S
PS
McCosker
C J
CJ
Kaan
A F
AF
D000553:Ambulatory Care; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004280:Dobutamine / Q000008:administration & dosage* / Q000627:therapeutic use; D004298:Dopamine / Q000008:administration & dosage* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006439:Hemodynamics / Q000187:drug effects; D006701:Home Nursing / Q000191:economics; D006801:Humans; D007262:Infusions, Intravenous / Q000191:economics / Q000379:methods*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D004280:Dobutamine; D004298:Dopamine